Curcumin-sophorolipid complex
The present invention relates to a complex comprising acidic sophorolipid and curcumin ((SL(A)+Cur), wherein, curcumin is solubilized and nano-encapsulated in acidic sophorolipid to improve the water solubility, stability and bioavailability of curcumin in order to enhance its therapeutic activity. Further, the invention provides pharmaceutical compositions comprising the present complex and methods to treat cancer in a subject using the said composition.
1. A curcumin-sophorolipid complex comprising acidic sophorolipid and curcumin in a ratio ranging from 6:1 to 1:1 (w/v).
2. The complex according to claim 1 , wherein the curcumin is solubilized and encapsulated in the acidic sophorolipid to improve solubility, stability, and bioavailability of the curcumin.
3. The complex according to claim 1 , wherein said complex comprises sophorolipid and curcumin in a ratio of 5:1.
4. The complex according to claim 1 , wherein said complex has a particle size ranging from 5 to 30 nm.
5. The complex according to claim 1 , wherein said complex is in aqueous form.
6. The complex according to claim 1 for use in treatment of breast cancer.
7. The complex according to claim 1 for use in preparation of medicament for treatment of breast cancer.
8. A process for the preparation of curcumin-sophorolipid complex according to claim 1 , wherein said process comprises the steps of:
(i) sonicating 80 to 90 (wt %) sophorolipid solution for a period ranging from 15 to 30minutes with addition of 10 to 20 (wt %) curcumin solution at a rate of 0.5 ml/min to obtain a solution; and
(ii) drying the solution of step (i) followed by addition of water for complete dispersion of curcumin to achieve a uniform dispersion;
(iii) filtering the uniform dispersion of step (ii) to obtain the curcumin-sophorolipid complex.
9. A pharmaceutical composition comprising curcumin-sophorolipid complex according to claim 1 and a pharmaceutically acceptable excipient, wherein the curcumin-sophorolipid complex ranges from 0.001 to 99.99% of total weight of the pharmaceutical composition.
10. The pharmaceutical composition according to claim 9 , wherein the composition comprises an agent having anti-oxidant, anti-cancer, or anti-adipogenic activity.
11. The pharmaceutical composition according to claim 9 , wherein the excipient is selected from the group consisting of tableting excipients, injectable excipients, and excipients for liquid dosage forms.
12. The pharmaceutical composition according to claim 9 , wherein the composition is formulated as a tablet, capsule, pellet, granule, oral powder, injectable powder,syrup, solution, liquid ampoule, dispersion, aerosol spray, semi-solid, softgel, aerosol, or suspension.
13. The pharmaceutical composition according to claim 10 , wherein the agent is selected from the group consisting of rituximab, bevacizumab, imatinib, leuprorelin, lenalido-midecetuximab, and trastuzumab.
14. A method of treating breast cancer in a subject, wherein the method comprises administering to a subject having breast cancer a therapeutically effective amount of the pharmaceutical composition according to claim 9 .
15. A method of treating breast cancer in a subject, wherein the method comprises administering to a subject having breast cancer a therapeutically effective amount of the pharmaceutical composition according to claim 10 .